Melanoma Research Review, Issue 66
In this issue:
Pretreatment emotional distress and neoadjuvant ICI blockade response
The features and management of AR to PD1 therapy
Trial of the CD40 agonistic antibody sotigalimab + nivolumab
Adjuvant nivolumab in resected stage IIB/C melanoma
The genetic risk of NM using a candidate gene approach
Risk factors for subsequent primary melanoma in patients with previous melanoma
Survival rates in patients diagnosed with MIS
The limited value of sentinel lymph node biopsy in lentigo malinga melanoma
Lower frequencies of circulating suppressive regulatory T cells with severe irAEs
Dabrafenib plus trametinib vs anti-PD1 for BRAF V600-mutant melanoma
Expert contributor
Professor Peter Hersey
Peter Hersey is an honorary Professor of Immuno Oncology in the University of Sydney and a faculty member of the Melanoma Institute Australia. He has conducted a number of phase I to III trials of immunotherapy in melanoma, including use of modified peptide antigens and dendritic cell vaccines. He has taken a leading role in […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.